Aptorum Group Limited (NASDAQ:APM) Sees Large Growth in Short Interest

Aptorum Group Limited (NASDAQ:APM) was the target of a large increase in short interest in October. As of October 15th, there was short interest totalling 2,700 shares, an increase of 22.7% from the September 30th total of 2,200 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average daily volume of 15,500 shares, the days-to-cover ratio is presently 0.2 days.

Institutional Investors Weigh In On Aptorum Group

A hedge fund recently bought a new stake in Aptorum Group stock. Murchinson Ltd. purchased a new stake in Aptorum Group Limited (NASDAQ:APM) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 14,000 shares of the company’s stock, valued at approximately $133,000. Murchinson Ltd. owned 0.27% of Aptorum Group at the end of the most recent reporting period. Hedge funds and other institutional investors own 3.80% of the company’s stock.

Aptorum Group Stock Down 10.3 %

Shares of APM opened at $1.48 on Tuesday. Aptorum Group has a twelve month low of $1.35 and a twelve month high of $17.49. The firm’s 50 day moving average price is $2.30 and its two-hundred day moving average price is $3.69.

About Aptorum Group

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A.